Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment

David Mischoulon, Stefania Lamon-Fava, Jacob Selhub, Judith Katz, George I. Papakostas, Dan V. Iosifescu, Albert S. Yeung, Christina M. Dording, Amy H. Farabaugh, Alisabet J. Clain, Lee Baer, Jonathan E. Alpert, Andrew A. Nierenberg, Maurizio Fava

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective. To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response. Methods. We screened 224 subjects (52% female, mean age 39 ± 11 years) with SCID-diagnosed major depressive disorder (MDD), and obtained 194 genetic samples. 49 subjects (49% female, mean age 36 ± 11 years) participated in a 12-week open clinical trial of fluoxetine 20-60 mg/day. Association between clinical response and C677T and A2756G polymorphisms, folate, B12, and homocysteine was examined. Results. Prevalence of the C677T and A2756G polymorphisms was consistent with previous reports (C/C=41%, C/T=47%, T/T=11%, A/A=66%, A/G=29%, G/G=4%). In the fluoxetine-treated subsample (n=49), intent-to-treat (ITT) response rates were 47% for C/C subjects and 46% for pooled C/T and T/T subjects (nonsignificant). ITT response rates were 38% for A/A subjects and 60% for A/G subjects (nonsignificant), with no subjects exhibiting the G/G homozygote. Mean baseline plasma B12 was significantly lower in A/G subjects compared to A/A, but folate and homocysteine levels were not affected by genetic status. Plasma folate was negatively associated with treatment response. Conclusion. The C677T and A2756G polymorphisms did not significantly affect antidepressant response. These preliminary findings require replication in larger samples.

Original languageEnglish (US)
Pages (from-to)76-86
Number of pages11
JournalCNS Spectrums
Volume17
Issue number2
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
Methylenetetrahydrofolate Reductase (NADPH2)
Fluoxetine
Major Depressive Disorder
Folic Acid
Homocysteine
Antidepressive Agents
Homozygote
Clinical Trials
Genes

Keywords

  • A2756G
  • Antidepressant
  • C677T
  • Depression
  • Fluoxetine
  • Methionine Synthase
  • Methylene Tetrahydrofolate Reductase
  • MS
  • MTHFR

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Mischoulon, D., Lamon-Fava, S., Selhub, J., Katz, J., Papakostas, G. I., Iosifescu, D. V., ... Fava, M. (2012). Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. CNS Spectrums, 17(2), 76-86. https://doi.org/10.1017/S1092852912000430

Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. / Mischoulon, David; Lamon-Fava, Stefania; Selhub, Jacob; Katz, Judith; Papakostas, George I.; Iosifescu, Dan V.; Yeung, Albert S.; Dording, Christina M.; Farabaugh, Amy H.; Clain, Alisabet J.; Baer, Lee; Alpert, Jonathan E.; Nierenberg, Andrew A.; Fava, Maurizio.

In: CNS Spectrums, Vol. 17, No. 2, 06.2012, p. 76-86.

Research output: Contribution to journalArticle

Mischoulon, D, Lamon-Fava, S, Selhub, J, Katz, J, Papakostas, GI, Iosifescu, DV, Yeung, AS, Dording, CM, Farabaugh, AH, Clain, AJ, Baer, L, Alpert, JE, Nierenberg, AA & Fava, M 2012, 'Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment', CNS Spectrums, vol. 17, no. 2, pp. 76-86. https://doi.org/10.1017/S1092852912000430
Mischoulon, David ; Lamon-Fava, Stefania ; Selhub, Jacob ; Katz, Judith ; Papakostas, George I. ; Iosifescu, Dan V. ; Yeung, Albert S. ; Dording, Christina M. ; Farabaugh, Amy H. ; Clain, Alisabet J. ; Baer, Lee ; Alpert, Jonathan E. ; Nierenberg, Andrew A. ; Fava, Maurizio. / Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment. In: CNS Spectrums. 2012 ; Vol. 17, No. 2. pp. 76-86.
@article{b2b76e4b7db646ef9966d009a4007321,
title = "Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment",
abstract = "Objective. To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response. Methods. We screened 224 subjects (52{\%} female, mean age 39 ± 11 years) with SCID-diagnosed major depressive disorder (MDD), and obtained 194 genetic samples. 49 subjects (49{\%} female, mean age 36 ± 11 years) participated in a 12-week open clinical trial of fluoxetine 20-60 mg/day. Association between clinical response and C677T and A2756G polymorphisms, folate, B12, and homocysteine was examined. Results. Prevalence of the C677T and A2756G polymorphisms was consistent with previous reports (C/C=41{\%}, C/T=47{\%}, T/T=11{\%}, A/A=66{\%}, A/G=29{\%}, G/G=4{\%}). In the fluoxetine-treated subsample (n=49), intent-to-treat (ITT) response rates were 47{\%} for C/C subjects and 46{\%} for pooled C/T and T/T subjects (nonsignificant). ITT response rates were 38{\%} for A/A subjects and 60{\%} for A/G subjects (nonsignificant), with no subjects exhibiting the G/G homozygote. Mean baseline plasma B12 was significantly lower in A/G subjects compared to A/A, but folate and homocysteine levels were not affected by genetic status. Plasma folate was negatively associated with treatment response. Conclusion. The C677T and A2756G polymorphisms did not significantly affect antidepressant response. These preliminary findings require replication in larger samples.",
keywords = "A2756G, Antidepressant, C677T, Depression, Fluoxetine, Methionine Synthase, Methylene Tetrahydrofolate Reductase, MS, MTHFR",
author = "David Mischoulon and Stefania Lamon-Fava and Jacob Selhub and Judith Katz and Papakostas, {George I.} and Iosifescu, {Dan V.} and Yeung, {Albert S.} and Dording, {Christina M.} and Farabaugh, {Amy H.} and Clain, {Alisabet J.} and Lee Baer and Alpert, {Jonathan E.} and Nierenberg, {Andrew A.} and Maurizio Fava",
year = "2012",
month = "6",
doi = "10.1017/S1092852912000430",
language = "English (US)",
volume = "17",
pages = "76--86",
journal = "CNS Spectrums",
issn = "1092-8529",
publisher = "MBL Communications",
number = "2",

}

TY - JOUR

T1 - Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment

AU - Mischoulon, David

AU - Lamon-Fava, Stefania

AU - Selhub, Jacob

AU - Katz, Judith

AU - Papakostas, George I.

AU - Iosifescu, Dan V.

AU - Yeung, Albert S.

AU - Dording, Christina M.

AU - Farabaugh, Amy H.

AU - Clain, Alisabet J.

AU - Baer, Lee

AU - Alpert, Jonathan E.

AU - Nierenberg, Andrew A.

AU - Fava, Maurizio

PY - 2012/6

Y1 - 2012/6

N2 - Objective. To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response. Methods. We screened 224 subjects (52% female, mean age 39 ± 11 years) with SCID-diagnosed major depressive disorder (MDD), and obtained 194 genetic samples. 49 subjects (49% female, mean age 36 ± 11 years) participated in a 12-week open clinical trial of fluoxetine 20-60 mg/day. Association between clinical response and C677T and A2756G polymorphisms, folate, B12, and homocysteine was examined. Results. Prevalence of the C677T and A2756G polymorphisms was consistent with previous reports (C/C=41%, C/T=47%, T/T=11%, A/A=66%, A/G=29%, G/G=4%). In the fluoxetine-treated subsample (n=49), intent-to-treat (ITT) response rates were 47% for C/C subjects and 46% for pooled C/T and T/T subjects (nonsignificant). ITT response rates were 38% for A/A subjects and 60% for A/G subjects (nonsignificant), with no subjects exhibiting the G/G homozygote. Mean baseline plasma B12 was significantly lower in A/G subjects compared to A/A, but folate and homocysteine levels were not affected by genetic status. Plasma folate was negatively associated with treatment response. Conclusion. The C677T and A2756G polymorphisms did not significantly affect antidepressant response. These preliminary findings require replication in larger samples.

AB - Objective. To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response. Methods. We screened 224 subjects (52% female, mean age 39 ± 11 years) with SCID-diagnosed major depressive disorder (MDD), and obtained 194 genetic samples. 49 subjects (49% female, mean age 36 ± 11 years) participated in a 12-week open clinical trial of fluoxetine 20-60 mg/day. Association between clinical response and C677T and A2756G polymorphisms, folate, B12, and homocysteine was examined. Results. Prevalence of the C677T and A2756G polymorphisms was consistent with previous reports (C/C=41%, C/T=47%, T/T=11%, A/A=66%, A/G=29%, G/G=4%). In the fluoxetine-treated subsample (n=49), intent-to-treat (ITT) response rates were 47% for C/C subjects and 46% for pooled C/T and T/T subjects (nonsignificant). ITT response rates were 38% for A/A subjects and 60% for A/G subjects (nonsignificant), with no subjects exhibiting the G/G homozygote. Mean baseline plasma B12 was significantly lower in A/G subjects compared to A/A, but folate and homocysteine levels were not affected by genetic status. Plasma folate was negatively associated with treatment response. Conclusion. The C677T and A2756G polymorphisms did not significantly affect antidepressant response. These preliminary findings require replication in larger samples.

KW - A2756G

KW - Antidepressant

KW - C677T

KW - Depression

KW - Fluoxetine

KW - Methionine Synthase

KW - Methylene Tetrahydrofolate Reductase

KW - MS

KW - MTHFR

UR - http://www.scopus.com/inward/record.url?scp=84869225065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869225065&partnerID=8YFLogxK

U2 - 10.1017/S1092852912000430

DO - 10.1017/S1092852912000430

M3 - Article

VL - 17

SP - 76

EP - 86

JO - CNS Spectrums

JF - CNS Spectrums

SN - 1092-8529

IS - 2

ER -